DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets Hard-to-Treat bone cancer
Disease control TerminatedThis early-phase trial tested a combination of two drugs—TQB2928 (an antibody that helps the immune system attack cancer cells) and anlotinib (a drug that cuts off tumor blood supply)—in 20 people with advanced osteosarcoma or other solid tumors that had stopped responding to sta…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Promising liposarcoma drug trial halted early
Disease control TerminatedThis study tested a new drug called TQB3616 for people with a rare type of fat tissue cancer called dedifferentiated liposarcoma that could not be removed by surgery. The goal was to see if the drug could slow down cancer growth compared to a placebo. The trial was stopped early …
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC